Moderna (MRNA) Income from Continuing Operations (2017 - 2026)
Moderna (MRNA) posted quarterly Income from Continuing Operations of 782000000.0 for Q2 2026, up 5.21% year-over-year from 743260368.66 in Q2 2025, and up 41.77% on a QoQ basis from 1343000000.0 in Q1 2026.
Moderna (MRNA) Income from Continuing Operations (2017 - 2026) Analysis & Trends
Moderna has reported Income from Continuing Operations for 10 years, with the latest figure at 782000000.0 in Q2 2026.
- Income from Continuing Operations for Q2 2026 came in at 782000000.0, up 5.21% year-over-year; the trailing twelve-month figure through Jun 2026 was 3151000000.0 (down 8.54% YoY), and the FY2025 annual result was 2822000000.0, up 20.75% from the prior year.
- Income from Continuing Operations climbed to 782000000.0 in Q2 2026, from 1343000000.0 in the prior quarter.
- Over five years, Income from Continuing Operations peaked at 3657000000.0 in Q1 2022 and troughed at 3630000000.0 in Q3 2023.
- A 5-year average of 270000000.0 and a median of 803500000.0 in 2025 frame the typical range for Income from Continuing Operations.
- The widest annual swing landed in 2022, when Income from Continuing Operations jumped 199.51%; it then plunged 1638.46% in 2025.
- A 5-year view of Income from Continuing Operations shows it stood at 1465000000.0 in 2022, then tumbled by 85.19% to 217000000.0 in 2023, then sank by 616.13% to 1120000000.0 in 2024, then advanced by 26.25% to 826000000.0 in 2025, then advanced by 5.33% to 782000000.0 in 2026.
- Per Business Quant data, the three most recent Income from Continuing Operations figures were 782000000.0 in Q2 2026, 1343000000.0 in Q1 2026, and 826000000.0 in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 1.10 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.30 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 482.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -644.37 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 237.01 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -3,096.02 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 81.49 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 164.49 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -13.27 Mn |
| 10 | Moderna | 25.26 Bn | 20.13 Bn | 52.00 Mn | -782.00 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -782.00 Mn |
| Mar 31, 2026 | -1.34 Bn |
| Dec 31, 2025 | -826.00 Mn |
| Sep 30, 2025 | -200.00 Mn |
| Jun 30, 2025 | -825.00 Mn |
| Mar 31, 2025 | -971.00 Mn |
| Dec 31, 2024 | -1.12 Bn |
| Sep 30, 2024 | 13.00 Mn |
| Jun 30, 2024 | -1.28 Bn |
| Mar 31, 2024 | -1.18 Bn |
| Dec 31, 2023 | 217.00 Mn |
| Sep 30, 2023 | -3.63 Bn |
| Jun 30, 2023 | -1.38 Bn |
| Mar 31, 2023 | 79.00 Mn |
| Dec 31, 2022 | 1.47 Bn |
| Sep 30, 2022 | 1.04 Bn |
| Jun 30, 2022 | 2.20 Bn |
| Mar 31, 2022 | 3.66 Bn |
| Dec 31, 2021 | 4.87 Bn |
| Sep 30, 2021 | 3.33 Bn |